MYC proto-oncogene, basic helix-loop-helix (bHLH) transcription factor (MYC)

The **MYC proto-oncogene**, encoding a basic helix-loop-helix leucine zipper (bHLH-LZ) transcription factor known simply as **Myc**, is a master regulator controlling numerous genes involved primarily in cell growth, proliferation, metabolism, differentiation, apoptosis suppression, and stem cell maintenance. The gene resides on chromosome 8q24.21 and produces an mRNA transcript characterized by conserved secondary structural elements particularly within untranslated regions that influence post-transcriptional regulation. At the molecular level, Myc binds specific DNA sequences called E-boxes (5'-CACGTG/CACTG), recruiting histone acetyltransferases which remodel chromatin facilitating active transcription. It also interacts with components regulating RNA polymerase II elongation complex enhancing efficient full-length transcript production. Beyond activating genes promoting proliferation such as cyclins and nucleotide biosynthesis enzymes it can repress certain targets via interaction with other factors like Miz1. Dysregulation—often amplification or overexpression—of this gene leads to aberrant cellular behavior contributing significantly to oncogenesis across diverse human cancers including lymphomas where increased c-myc correlates with poor prognosis. Despite being historically labeled “undruggable” at the protein level due mainly to lack of enzymatic pockets suitable for small molecules there is growing interest exploiting unique features within its messenger RNA structure offering novel avenues for targeted therapy development.[1][2][3][4] In summary: MYC represents both an essential physiological regulator fundamental for normal cellular function but also one whose misregulation drives malignant transformation making it an important focus for cancer research aiming at innovative therapeutic strategies.[5]

Other names

c-MycCMYCbHLH transcription factor MycProto-oncogene c-Myc

For drugs under development targeting this molecule: - Modulation of mRNA secondary structure motifs affecting translation efficiency or miRNA accessibility leading to decreased oncogenic protein production [1]. - Inhibition strategies aimed at disrupting interactions between Myc protein and DNA or co-factors involved in transcriptional activation. No clinically established mechanisms yet due to lack of direct inhibitors.